Oregovomab not checked

CanariaBio Inc. · MAb-B43.13 · Monoclonal antibody B43.13

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
4 active
4 in total · 1 in the EU
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
How it’s given
“2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes”In the company’s words, NCT04498117 on ClinicalTrials.gov
Tested for
Ovarian Cancer (2 trials), Ovarian Serous Adenocarcinoma (2 trials), Fallopian Tube Neoplasms (2 trials), Peritoneal Cancer (2 trials), Peritoneal Carcinoma (2 trials), Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Fallopian Tube Adenocarcinoma and 12 more
Main trialPhase 3
“Study to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with newly diagnosed advanced ovarian cancer who have undergone optimal debulking.”In the company’s words, NCT04498117 on ClinicalTrials.gov
Other names
MAb-B43.13 · Monoclonal antibody B43.13

Other drugs for Ovarian Cancer

All 265 drugs for Ovarian Cancer

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 26 Dec 2026 Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
Phase 2Active, not recruiting 30 Dec 2026 A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
Phase 2Active, not recruiting 15 May 2027 Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer
Phase 1/2Active, not recruiting 30 Oct 2025 Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Oregovomab

Following is part of Solo: you see every change to Oregovomab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in